In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories

In Health Care You Don’t Become A Unicorn Overnight

The pandemic has shaken up investor priorities and changed the outlook for health care start-ups – or has it? Nooman Haque managing director, life sciences and healthcare at Silicon Valley Bank, gives his view of what has changed over the past year, and looks at future trends.

Deals Medical Device

Will 2021 Be A Turning Point For Pharnext?

After manufacturing issues disrupted a Phase III study for its lead pipeline candidate, Pharnext believes it is back on track with new management, a fresh clinical trial and strong guidance from regulators. New CEO David Horn Solomon has blockbuster expectations for the company’s rare disease drug. 

Business Strategies C-Suite Speaks Commercial

Carving Out New Spaces In Cancer Immunotherapy

With a combined $335m raised in a crossover series B funding and an IPO last summer, Cambridge, MA-based iTeos Therapeutics has the juice to move its two cancer immunotherapy clinical programs forward.

Financing ImmunoOncology Leadership

Putting The Patient First: The Challenge And Opportunities To Improve Rare-Disease Therapy Development


Advances in identifying the genetic causes of diseases, and particularly cancers, coupled with regulatory incentives to encourage the development of therapeutic approaches to once poorly managed orphan diseases have fueled a surge in exciting new medicines. To address some of these issues and explore potential solutions, Simbec-Orion in collaboration with Informa Pharma Intelligence convened a round table of experts attending the BIO International Convention

Read More
Data Spotlight

Titans Of Pharma 2020: 15 Leading CEOs Bag $266m In Compensation

See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.

Making Progress Against Rare Diseases

Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.

Accessing CAR-T Therapies

Infographic: There are two CAR-T therapies on the market, both of which secured their first approvals in 2017. The pipeline of autologous and allogeneic CAR-T options is busy with several candidates in clinical studies. However, getting approval is only one part of getting these breakthrough therapies to patients.

Growth Explore this Topic

Set Alert for Growth

Latest From Growth

In Vivo’s Deals Of The Year 2020: Winners Revealed

For In Vivo's 13th annual Deals of the Year contest, we selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.

Business Strategies Commercial

Are SPACs Good Or Bad For Biopharma?

Special Purpose Acquisition Companies (SPACs) homed in on the biopharma industry in 2020, providing biotech companies with a faster and looser route to the public market. Is there a downside?

Business Strategies Commercial

In Health Care You Don’t Become A Unicorn Overnight

The pandemic has shaken up investor priorities and changed the outlook for health care start-ups – or has it? Nooman Haque managing director, life sciences and healthcare at Silicon Valley Bank, gives his view of what has changed over the past year, and looks at future trends.

Deals Medical Device

Innovation Explore this Topic

Set Alert for Innovation

Latest From Innovation

VC View: Riding The Waves Of Asia’s Healthtech Explosion

Asia continues to gain attention for its healthtech innovation and adoption activity, and VC investors have seen the merits of a maintaining a focus on this newly emerging regional innovation hotspot, regardless of the pandemic.

VC Playbook Medical Device

COVID-19 Promise Fulfilled, But Where Next For mRNA Vaccines?

After a baptism of fire during the coronavirus pandemic, mRNA vaccine technology has earned its stripes. In less than a year, mRNA vaccines have been catapulted from interesting pipeline prospects to game-changers in the fight against COVID-19. But what does this success mean for the future of the technology?

Coronavirus COVID-19 Innovation

Big Pharma Holds Steady With One-Third Of Novel Agents Approved In US In 2020

Gilead and Roche ended the year involved in three novel agents apiece, thanks to a combination of internal research and external licensing.

Approvals Companies

Leadership Explore this Topic

Set Alert for Leadership

Latest From Leadership

Execs On The Move, February 2021

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Appointments BioPharmaceutical

VC View: Riding The Waves Of Asia’s Healthtech Explosion

Asia continues to gain attention for its healthtech innovation and adoption activity, and VC investors have seen the merits of a maintaining a focus on this newly emerging regional innovation hotspot, regardless of the pandemic.

VC Playbook Medical Device

Direct To Consumer Approach Underscores Femtech’s Disruptive Potential

A new technology accelerator, FemTech Lab, will support the scale-up of at least 10 firms in 2021 that have innovative solutions for issues affecting women’s health and wellbeing. The founders talk to In Vivo about their view of the femtech market and how it will impact traditional health care.

Commercial Companies

Market Access Explore this Topic

Set Alert for Market Access

Latest From Market Access

Is Pharma Doing Enough To Enable Access To COVID-19 Vaccines Everywhere?

The race to develop COVID-19 vaccines is intensifying long-standing debate over the ability of lower-income countries to gain affordable access to needed medical treatments. Patient advocates argue that drug makers and wealthy governments are striking deals that place poor countries at a disadvantage. The pharmaceutical industry, however, maintains it is moving as quickly as possible to not only discover safe and effective vaccines, but to enable equitable distribution.    

Coronavirus COVID-19 Market Access

How Pharma Can Navigate Ups And Downs Of Vertical Integration In US

Together, we will improve patient health and experiences while lowering costs across the continuum of care.” This quote, from Andrew Witty, CEO of US health services management company Optum, after the company sealed its acquisition of DaVita Medical Group in 2019, encapsulates the oft-declared goals of vertical integration: efficiencies, improved quality of care, reduced costs. But is this the reality?

Business Strategies Commercial

Options, Expertise And Risk Tolerance Needed For Successful Value-Based Contracts

Biohaven Pharmaceuticals developed six different value-based contracting options to support the launch of acute migraine therapy, Nurtec ODT. Despite contract complexity and lingering regulatory risk, payers are aggressively pursuing value-based contracts, leading even small biopharmas to invest in strong health economics capabilities.

Business Strategies Commercial

Market Intelligence Explore this Topic

Set Alert for Market Intelligence

Latest From Market Intelligence

Unlocking Resiliency In Clinical Research And Improving Access For All

The pharma industry has grappled for years with its role in improving equitable access to clinical research. The needle has moved, but impactful changes have not come quickly enough. 

Clinical Trials Research and Development Strategies

Compensation For COVID-19 Vaccine Injuries In India: Stark Fault Lines?

Experts discuss the complexities of pursuing compensation for COVID-19 vaccine-related injuries in India. Is there a case for ‘absolute liability’ for all injuries related to the two fast-tracked vaccines currently available, or alternatively a no-fault compensation program?

Asia Pacific India

SPACs Surge In 2020

Despite the COVID-19 chaos felt by many industries in 2020, biopharma IPOs recorded a banner year – including a marked rise in the use of special purpose acquisition companies (SPACs), also known as blank check companies. 

Business Strategies Deals
UsernamePublicRestriction

Register